1242273-06-8

Basic information

• Product Name: (7R)-4-fluoro-7-[5-[(4-fluorophenyl)methyl]-1H-1,2,3-triazol-1-yl]-6,7,8,9-tetrahydro-pyrido[1,2-a]indole-10-acetic acid ethyl ester
• Synonyms: (7R)-4-fluoro-7-[5-[(4-fluorophenyl)methyl]-1H-1,2,3-triazol-1-yl]-6,7,8,9-tetrahydro-pyrido[1,2-a]indole-10-acetic acid ethyl ester
• CAS NO: 1242273-06-8
• Molecular Weight: 450.488
• Mol File: 1242273-06-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (7R)-4-fluoro-7-[5-[(4-fluorophenyl)methyl]-1H-1,2,3-triazol-1-yl]-6,7,8,9-tetrahydro-pyrido[1,2-a]indole-10-acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (7R)-4-fluoro-7-[5-[(4-fluorophenyl)methyl]-1H-1,2,3-triazol-1-yl]-6,7,8,9-tetrahydro-pyrido[1,2-a]indole-10-acetic acid ethyl ester(1242273-06-8)
• EPA Substance Registry System: (7R)-4-fluoro-7-[5-[(4-fluorophenyl)methyl]-1H-1,2,3-triazol-1-yl]-6,7,8,9-tetrahydro-pyrido[1,2-a]indole-10-acetic acid ethyl ester(1242273-06-8)

Safety Data

• Hazardous Substances Data: 1242273-06-8(Hazardous Substances Data)

Upstream product

• 1242273-00-2 4-fluoro-6,7,8,9-tetrahydro-7-oxo-pyrido[1,2-a]indole-10-acetic acid ethyl ester 
• 1242272-99-6 [4-[3-(2-ethoxy-2-oxoethyl)-7-fluoro-1H-indol-2-yl]-2-oxobutyl]dimethyl-sulfoxonium 
• 1242272-98-5 3-(2-ethoxy-2-oxoethyl)-7-fluoro-1H-indole-2-propanoic acid ethyl ester 
• 1242272-97-4 diethyl 4-[(2-bromo-6-fluorophenyl)imino]heptanedioate 
• 14160-68-0 4,4-diethoxy-heptanedioic acid 1,7-diethyl ester 
• 6317-49-3 4-oxopimelate 
• 133218-06-1 4-fluoro-1-[3-(trimethylsilyl)prop-2-yn-1-yl]benzene 
• 459-46-1 4-Fluorobenzyl bromide 
• 1242273-05-7 (7R)-7-azido-4-fluoro-6,7,8,9-tetrahydro-pyrido[1,2-a]indole-10-acetic acid ethyl ester 
• 70090-68-5 1-fluoro-4-(prop-2-yn-1-yl)benzene 

Downstream Products

• 1242272-15-6 MK-1029 

Relevant articles and documents

Harnessing the Power of Catalysis for the Synthesis of CRTH2 Antagonist MK-1029

The synthetic strategy utilized to prepare clinical supplies of CRTH2 antagonist MK-1029 is described. Specifically, the approach communicated is predicated on the intervention of five distinct catalytic methods, using three separate metals and an enzyme, to enable successful construction of this complex active pharmaceutical ingredient.